1 active not recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Invasive Bladder Sarcomatoid Urothelial Carcinoma: new trials by email Literature Review of Invasive Bladder Sarcomatoid Urothelial Carcinoma trials Research Report on Invasive Bladder Sarcomatoid Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-22 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
Carcinoma, Renal Cell (2) · Penile Neoplasms (2) · Urethral Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Carcinoma, Transitional Cell (1) · Prostatic Neoplasms (1) · Urachal adenocarcinoma (1) · Ureteral Neoplasms (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Penile Diseases (2)
CTLA-4 Antigen (2) · Ipilimumab (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · cabozantinib (2) · Biopsy (1)
National Cancer Institute (NCI) (2)
United States (2) · Puerto Rico (1)
Andrea B Apolo (2)
PMID 35031545, PMID 32915679, PMID 38954785
U10CA180821 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)